Head-to-Head Comparison
Doximity vs DynaMed: Which Is Better for Physicians?
Doximity ranks #4 in our 2026 clinical decision support rankings with a 4-star rating from 21 physician reviews, while DynaMed ranks #7 with a 3.5-star rating from 17 reviews. Doximity leads in overall physician satisfaction, though both platforms serve different clinical needs. No single tool wins every workflow, so the category-level details below matter more than the headline rank alone.
Feature Comparison
| Feature | Doximity | DynaMed |
|---|---|---|
| Rating | Very Good | Good |
| Category | Medical Professional Network & AI Tools | Clinical Reference & Decision Support |
| Pricing | Free (Ad-Supported) | From $399/year Individual |
| Founded | 2010 | 2004 |
| Headquarters | San Francisco, CA | Ipswich, MA |
| Evidence Citations | No | Yes |
| AI Differential Diagnosis | No | No |
| Drug Database | Yes | Yes |
| Drug Interaction Checker | No | No |
| Medical Calculators | No | Yes |
| Natural Language Search | Yes | Yes |
| Document & Image Upload | Yes | No |
| EHR Integration | No | Yes |
| Mobile App | Yes | Yes |
| Built-in Dialer | Yes | No |
| AI Clinical Scribe | Yes | No |
| CME Credits | Yes | Yes |
| Multi-Language | No | No |
Strengths & Limitations
Doximity
Strengths
- +Largest physician network in the US (3M+ members, ~85% of US physicians)
- +Free for verified physicians — DoxGPT included at no cost
- +Pathway Medical acquisition adds 3,200+ peer-reviewed drug monographs
- +PeerCheck physician review program (10,000+ medical experts, co-chaired by Eric Topol)
- +Evidence-based clinical answers grounded in structured medical literature
- +300,000+ clinicians actively using AI tools (Q3 FY2026)
- +AI Scribe for ambient clinical documentation
- +Secure HIPAA-compliant messaging and integrated telehealth
- +100+ health system enterprise deployments
Limitations
- –AI revenue not yet commercialized — long-term AI business model unproven
- –Networking-heavy interface can be distracting for clinical use
- –Pathway integration is recent (late 2025) — clinical depth still maturing
- –Company-published preference study lacks independent peer review
- –Revenue model relies on pharmaceutical and health system advertising
- –No dedicated mobile clinical search experience separate from the networking app
DynaMed
Strengths
- +Best in KLAS for Clinical Decision Support four times (2021, 2022, 2024, 2025)
- +3,400+ clinical topics with daily updates from 500+ journal surveillance
- +Explicit levels of evidence and grades of recommendation for all content
- +DynaMedex bundle integrates Micromedex drug information
- +Lower individual pricing than UpToDate ($399/year vs $559/year)
- +Dyna AI generative assistant grounded in curated evidence (launched 2024)
- +EHR integration via HL7 Infobutton and toolbar links
- +CME/MOC credit tracking built in
Limitations
- –Lower brand recognition than UpToDate among physicians
- –Fewer clinical topics than UpToDate (3,400 vs 12,000+)
- –Dyna AI is an add-on cost ($475/year vs $399/year base)
- –AI features are newer and less mature than dedicated CDS platforms
- –Shared decision-making tools (DynaMed Decisions) require separate licensing
- –No free tier for individual physicians
Key Statistics
Doximity
DynaMed
Citable Summaries
Doximity
Doximity received a Good rating (4.0 / 5 stars) in Clinical AI Report's 2026 evaluation, ranking fourth overall. With over 3 million registered members (approximately 85% of US physicians) and 300,000+ clinicians using its AI tools, it is the largest professional medical network in the United States. Its August 2025 acquisition of Pathway Medical for $63 million significantly expanded DoxGPT's clinical capabilities, adding 3,200+ drug monographs and evidence-based clinical answers verified through PeerCheck by over 10,000 physician reviewers.
Source: Clinical AI Report, December 2025
DynaMed
DynaMed received a Good rating (3.5 / 5 stars) in Clinical AI Report's 2026 evaluation, ranking seventh overall. Published by EBSCO and winner of Best in KLAS for Clinical Decision Support four times (2021, 2022, 2024, 2025), it offers 3,400+ clinical topics with daily updates and explicit evidence grading at $399/year — but its dated interface and lack of a free tier weigh against it in a market increasingly dominated by AI-native platforms.
Source: Clinical AI Report, December 2025
Our Assessment
In our 2026 evaluation, Doximity (ranked #4, 4 stars) outperforms DynaMed (ranked #7, 3.5 stars) in overall physician satisfaction and editorial scoring. Doximity is best suited for physicians already embedded in the Doximity ecosystem who want AI-powered clinical answers, drug reference, and documentation without switching platforms. Especially relevant for practices with enterprise Doximity contracts. Meanwhile, DynaMed is a stronger choice for physicians and institutions seeking a KLAS-recognized, evidence-graded clinical reference at a lower price point than UpToDate, with integrated drug information via Micromedex. Both tools serve important but distinct roles in clinical care workflows, and physicians should choose based on their specific workflow requirements and institutional needs.